About Aldo-keto reductase family 1 member C1
Aldo-keto reductase family 1 member C1 (AKR1C1) is a protein
from Homo sapiens identified by UniProt accession
Q04828, 323 residues long.
MolForge cross-references it against 0 known binders and
151 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member C1 |
| UniProt accession | Q04828 |
| Gene | AKR1C1 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (151)
Diseases linked to this target (Open Targets).
- BMI-adjusted waist-hip ratio · score 0.36
- lean body mass · score 0.35
- waist-hip ratio · score 0.34
- body height · score 0.34
- BMI-adjusted waist circumference · score 0.30
- appendicular lean mass · score 0.28
- peak expiratory flow · score 0.28
- fat body mass · score 0.27
- ovarian cancer · score 0.25
- BMI-adjusted hip circumference · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q04828-F1 | alphafold | PREDICTED | 97.59 | — |
Amino-acid sequence (323 residues)
MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEATKL AIEAGFRHID SAHLYNNEEQ VGLAIRSKIA DGSVKREDIF YTSKLWCNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV SVKPGEEVIP KDENGKILFD TVDLCATWEA VEKCKDAGLA KSIGVSNFNR RQLEMILNKP GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN RNVRYLTLDI FAGPPNYPFS DEY
Explore Aldo-keto reductase family 1 member C1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets